Literature DB >> 27519213

DNA Topoisomerase II-alpha as a marker of cell proliferation in endocrine and other neoplasms.

J A Holden1.   

Abstract

DNA topoisomerases are enzymes that are able to link and unlink DNA strands. They are classified as type I or type II topoisomerase if they catalyze transient single-strand (topo I) or double-strand (topo II) DNA breaks. Topo II-alpha has been used as a proliferation marker and it can also serve as a molecular target for a variety of anticancer drugs that are used clinically.Topo II-alpha expression is similar to MIB1 immunoreactivity in breast, ovarian, cervix, gastric, endometrial, adrenocortical, and hematological malignancies. In a study of adrenocortical tumors with metastases topo II was significantly higher than in tumors without metastases.Studies of topo II-alpha expression may provide information about the biological behavior of specific tumors and may also provide insights into the role that this enzyme plays in the response of human cancers to topo II-targeted anticancer drugs.

Entities:  

Keywords:  Cell proliferation; MIB1; adrenocortical tumors; topoisomerase II-alpha

Year:  1999        PMID: 27519213     DOI: 10.1007/BF02739821

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  48 in total

1.  Chromosome assembly in vitro: topoisomerase II is required for condensation.

Authors:  Y Adachi; M Luke; U K Laemmli
Journal:  Cell       Date:  1991-01-11       Impact factor: 41.582

Review 2.  Eukaryotic DNA topoisomerase II beta.

Authors:  C A Austin; K L Marsh
Journal:  Bioessays       Date:  1998-03       Impact factor: 4.345

3.  Topoisomerase II.etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes.

Authors:  D A Burden; P S Kingma; S J Froelich-Ammon; M A Bjornsti; M W Patchan; R B Thompson; N Osheroff
Journal:  J Biol Chem       Date:  1996-11-15       Impact factor: 5.157

4.  Transfection of human topoisomerase II alpha into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene.

Authors:  T Asano; T An; J Mayes; L A Zwelling; E S Kleinerman
Journal:  Biochem J       Date:  1996-10-01       Impact factor: 3.857

5.  Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26.

Authors:  C V Catapano; G M Carbone; F Pisani; J Qiu; D J Fernandes
Journal:  Biochemistry       Date:  1997-05-13       Impact factor: 3.162

6.  Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.

Authors:  J L Nitiss; Y X Liu; P Harbury; M Jannatipour; R Wasserman; J C Wang
Journal:  Cancer Res       Date:  1992-08-15       Impact factor: 12.701

7.  Proliferation Markers and Their Uses in the Study of Endocrine Tumors.

Authors:  Giuseppe Pelosi; Giuseppe Zamboni
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

8.  Immunohistochemical Analysis of the Cell Cycle-Associated Antigens Ki-67 and Retinoblastoma Protein in Parathyroid Carcinomas and Adenomas.

Authors:  Ricardo V. Lloyd; J. Aidan Carney; Jorge A. Ferreiro; Long Jin; Geoffrey B. Thompson; Jon A. Van Heerden; Clive S. Grant; Peter C. Wollan
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

9.  Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.

Authors:  G Cattoretti; M H Becker; G Key; M Duchrow; C Schlüter; J Galle; J Gerdes
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

10.  Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas.

Authors:  K Onda; R L Davis; M Shibuya; C B Wilson; T Hoshino
Journal:  Cancer       Date:  1994-10-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.